Goldman Pharma View: Buy AGN, Sell FRX, MRX A Takeover Target
May 25, 2012 at 10:37 AM EDT
A recent selloff in specialty pharmaceuticals has creating a buying opportunity, according to Goldman Sachs analyst Gregory Waterman, but he thinks investors should be discriminating. Allergan (AGN) is his top pick, a best-in-breed name that’s at a nice entry point. “Mid-teens EPS growth remains scarce in healthcare and AGN is structurally well positioned given: (1) [...]
